CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

17-Apr-2024 - CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...

Scientists develop artificial intelligence method to predict anti-cancer immunity

Machine learning algorithms are shedding light on neoantigen T cell-receptor pairs

28-Sep-2021 - Researchers and data scientists at UT Southwestern Medical Center and the University of Texas MD Anderson Cancer Center have developed an artificial intelligence technique that can identify which cell surface peptides produced by cancer cells called neoantigens are recognized by the immune ...

Protein inhibitor drug safe and effective with durable remissions in acute myeloid leukemia patients

04-Jun-2018 - Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. The multi-center Phase I trial, led by researchers at The ...

Merck and MD Anderson Cancer Center Enter Three-Year Strategic Collaboration

10-Jan-2017 - Merck and The University of Texas MD Anderson Cancer Center announced a three-year strategic collaboration, with the aim of more quickly advancing the development of investigational cancer therapies in four cancers – breast, colorectal, glioblastoma and leukemia. “This collaboration illustrates ...

Dietary glycemic index linked to lung cancer risk in select populations

07-Mar-2016 - Consuming a diet with a high glycemic index, a classification of how rapidly carbohydrates elevate blood sugar levels, was independently associated with an increased risk of developing lung cancer in non-Hispanic whites, according to a new epidemiologic study from The University of Texas MD ...

Sugar in western diets increases risk for breast cancer tumors and metastasis

05-Jan-2016 - The high amounts of dietary sugar in the typical Western diet may increase the risk of breast cancer and metastasis to the lungs, according to a study at The University of Texas MD Anderson Cancer Center. The findings demonstrated dietary sugar's effect on an enzymatic signaling pathway known as ...

First-in-class investigational therapeutic shows early promise for lymphoma patients

11-Nov-2015 - Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. The study was published in Clinical Cancer ...

CytomX and MD Anderson Cancer Center enter collaboration for Probody-enabled CAR-NK cell therapies

09-Nov-2015 - CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) ...

Compared to conventional radiation therapy IMRT associated with lesser side effects

Also better tolerance of chemotherapy is achieved in lung cancer patients

19-Oct-2015 - An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer (NSCLC) has shown that those who received intensity modulated radiation therapy (IMRT) had less severe lung toxicity and were able to better tolerate their chemotherapy, compared to ...

Modified CAR T cells can preferentially target cancer cells and spare normal cells

02-Sep-2015 - Engineering chimeric antigen receptor (CAR) T cells to lower their affinity for the protein epithelial growth factor receptor (EGFR) made the cells preferentially recognize and eliminate tumor cells that have high amounts of EGFR while sparing normal cells that have lower amounts of the protein, ...